Linked Life Data

11894013

Source:http://linkedlifedata.com/resource/pubmed/id/11894013

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1 Suppl 4
pubmed:dateCreated
2002-3-14
pubmed:abstractText
Overexpression of the epidermal growth factor receptor (EGFR) has been observed in a wide variety of human cancers and is associated with a poor clinical prognosis. In many cases, growth of the tumor cells is dependent on EGFR-mediated signals, because inhibition of binding of factors to the EGFR leads to cell death. Using XenoMouse technology, a fully human EGFR-specific monoclonal antibody, ABX-EGF, with high affinity (5 x 10(-11) mol/L) has been generated. ABX-EGF blocks binding of both epidermal growth factor and transforming growth factor alpha to the EGFR, inhibits tyrosine phosphorylation of the EGFR, and inhibits cellular proliferation. In vivo, ABX-EGF not only blocks formation of human epidermoid carcinoma A431 xenografts in athymic mice, but also mediates therapeutic elimination of established tumors and acts cooperatively with chemotherapeutics in mediating tumor regression. These observations provide a strong basis for the development of ABX-EGF as a therapeutic agent for human solid tumors that overexpress EGFR.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0093-7754
pubmed:author
pubmed:issnType
Print
pubmed:volume
29
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
47-50
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed:year
2002
pubmed:articleTitle
Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment.
pubmed:affiliation
Department of Cancer Biology, Immunex Corporation, Seattle, WA 98101, USA.
pubmed:publicationType
Journal Article, Review